RU2020109376A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2020109376A3 RU2020109376A3 RU2020109376A RU2020109376A RU2020109376A3 RU 2020109376 A3 RU2020109376 A3 RU 2020109376A3 RU 2020109376 A RU2020109376 A RU 2020109376A RU 2020109376 A RU2020109376 A RU 2020109376A RU 2020109376 A3 RU2020109376 A3 RU 2020109376A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/343,999 US10342785B2 (en) | 2016-11-04 | 2016-11-04 | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
US15/343,999 | 2016-11-04 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2018117891A Division RU2717331C2 (ru) | 2016-11-04 | 2017-11-02 | Применение антагонистов рецептора ep4 для лечения nash-ассоциированного рака печени |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2020109376A RU2020109376A (ru) | 2020-04-29 |
RU2020109376A3 true RU2020109376A3 (ru) | 2020-10-27 |
RU2762193C2 RU2762193C2 (ru) | 2021-12-16 |
Family
ID=60582639
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2018117891A RU2717331C2 (ru) | 2016-11-04 | 2017-11-02 | Применение антагонистов рецептора ep4 для лечения nash-ассоциированного рака печени |
RU2020109376A RU2762193C2 (ru) | 2016-11-04 | 2017-11-02 | Применение антагонистов рецептора ep4 для лечения nash-ассоциированного рака печени |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2018117891A RU2717331C2 (ru) | 2016-11-04 | 2017-11-02 | Применение антагонистов рецептора ep4 для лечения nash-ассоциированного рака печени |
Country Status (12)
Country | Link |
---|---|
US (2) | US10342785B2 (ru) |
EP (1) | EP3344296B1 (ru) |
JP (1) | JP6516341B2 (ru) |
KR (1) | KR20180064438A (ru) |
CN (1) | CN108289960B (ru) |
BR (1) | BR112018007947A2 (ru) |
CA (1) | CA3000237C (ru) |
ES (1) | ES2729961T3 (ru) |
HK (2) | HK1251162B (ru) |
MX (1) | MX2018005715A (ru) |
RU (2) | RU2717331C2 (ru) |
WO (1) | WO2018084230A1 (ru) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2019255196A1 (en) * | 2018-04-16 | 2020-11-12 | Arrys Therapeutics, Inc. | EP4 inhibitors and use thereof |
JP2021530487A (ja) * | 2018-07-11 | 2021-11-11 | アリーズ セラピューティクス, インコーポレイテッド | Ep4阻害剤およびその合成 |
WO2020151566A1 (zh) | 2019-01-22 | 2020-07-30 | 凯复制药有限公司 | 抑制pge2/ep4信号传导的化合物、其制备方法及其在医药上的应用 |
EP3722319A1 (en) * | 2019-04-09 | 2020-10-14 | Rottapharm Biotech S.r.l. | Pharmaceutical combination of an ep4 antagonist and immune checkpoint inhibitors for the treatment of tumours |
CN110386941A (zh) * | 2019-08-15 | 2019-10-29 | 上海邦耀生物科技有限公司 | Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗 |
CN110680555B (zh) * | 2019-11-12 | 2021-06-01 | 重庆医药高等专科学校 | 一种裸鼠皮下成瘤装置 |
WO2021205367A1 (en) * | 2020-04-08 | 2021-10-14 | Askat Inc. | Use of ep4 receptor antagonists for the treatment of liver cancer, melanoma, lymphoma and leukemia |
CN113577267B (zh) * | 2021-09-06 | 2022-04-08 | 江西北正干细胞生物科技有限公司 | Nk细胞和抗体的药物组合物及其在治疗癌症中的用途 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2274378T3 (es) | 1999-08-10 | 2007-05-16 | Glaxo Group Limited | Ligando del receptor ep4 y uso contra dolor neuropatico, cancer de colon,hiv y migraña. |
WO2001062708A1 (fr) | 2000-02-22 | 2001-08-30 | Ono Pharmaceutical Co., Ltd. | Derives d'acide benzoique, procede de production desdits derives, et medicament contenant ces derives comme principe actif |
US6710205B2 (en) | 2000-02-22 | 2004-03-23 | Ono Pharmaceutical Co., Ltd. | Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient |
HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
AU2003216579A1 (en) | 2002-04-12 | 2003-10-27 | Pfizer Inc. | Imidazole compounds as anti-inflammatory and analgesic agents |
KR20040101381A (ko) | 2002-04-16 | 2004-12-02 | 후지사와 야꾸힝 고교 가부시키가이샤 | 신규한 용도 |
MXPA05006828A (es) | 2002-12-23 | 2005-09-08 | Wyeth Corp | Anticuerpos contra pd-1, y sus usos. |
BRPI0414130B8 (pt) * | 2003-09-03 | 2021-05-25 | Askat Inc | compostos de fenilamida ou piridilamida, seu uso e composições farmacêuticas que os compreendem. |
US20090036495A1 (en) | 2004-04-20 | 2009-02-05 | Pfizer, Inc. | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists |
WO2005105733A1 (en) | 2004-05-04 | 2005-11-10 | Pfizer Japan Inc. | Ortho substituted aryl or heteroaryl amide compounds |
AU2005238291A1 (en) | 2004-05-04 | 2005-11-10 | Pfizer Inc. | Substituted methyl aryl or heteroaryl amide compounds |
US7960407B2 (en) | 2005-03-11 | 2011-06-14 | Requalia Pharma Inc. | Crystal forms of an imidazole derivative |
SI2161336T1 (sl) | 2005-05-09 | 2013-11-29 | Ono Pharmaceutical Co., Ltd. | Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki |
US8013159B2 (en) | 2005-05-19 | 2011-09-06 | Merck Canada Inc. | Quinoline derivatives as EP4 antagonists |
BRPI0613361A2 (pt) | 2005-07-01 | 2011-01-04 | Medarex Inc | anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1 |
EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
AU2009296392B2 (en) | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제 |
KR20210060670A (ko) | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | 항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도 |
BRPI1014174B8 (pt) | 2009-04-22 | 2021-05-25 | Askat Inc | uso de um composto selecionado a partir de 4-((1s)-1-{[5-cloro-2-(4-fluorofenóxi)benzoil]amino}etil)ácido benzóico, 4-[(1s)-1-({[5-cloro-2-(3-fluorofenóxi)piridin-3-il]carbonil}amino)etil]ácido benzóico e 3-[2-(4-{2-etil-4,6-dimetil-1h-imidazo[4,5-c]piridin-1-il}fenil)etil]-1-[(4-metilbenzeno)sulfonil]urea para tratamento de um câncer epitelial relacionado à pge2 |
PL2482849T3 (pl) | 2009-09-30 | 2018-11-30 | Memorial Sloan-Kettering Cancer Center | Skojarzona immunoterapia w leczeniu nowotworu |
EP2538978B1 (en) * | 2010-02-22 | 2016-09-07 | RaQualia Pharma Inc. | Use of an ep4 receptor antagonist in the treatment of allergic contact dermatitis and psoriasis |
WO2013040316A1 (en) | 2011-09-16 | 2013-03-21 | Galectin Therapeutics, Inc. | Galactomannan polysaccharide composition for the treatment of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease |
WO2013090552A1 (en) | 2011-12-13 | 2013-06-20 | Yale University | Compositions and methods for reducing ctl exhaustion |
BR112016013963A2 (pt) * | 2013-12-17 | 2017-10-10 | Genentech Inc | terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1 |
US20170182003A1 (en) | 2014-05-23 | 2017-06-29 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of cancer |
-
2016
- 2016-11-04 US US15/343,999 patent/US10342785B2/en active Active
-
2017
- 2017-11-02 MX MX2018005715A patent/MX2018005715A/es active IP Right Grant
- 2017-11-02 EP EP17809396.9A patent/EP3344296B1/en active Active
- 2017-11-02 CA CA3000237A patent/CA3000237C/en active Active
- 2017-11-02 BR BR112018007947A patent/BR112018007947A2/pt not_active Application Discontinuation
- 2017-11-02 KR KR1020187012103A patent/KR20180064438A/ko not_active Application Discontinuation
- 2017-11-02 ES ES17809396T patent/ES2729961T3/es active Active
- 2017-11-02 RU RU2018117891A patent/RU2717331C2/ru active
- 2017-11-02 CN CN201780004254.2A patent/CN108289960B/zh active Active
- 2017-11-02 JP JP2018516877A patent/JP6516341B2/ja active Active
- 2017-11-02 RU RU2020109376A patent/RU2762193C2/ru active
- 2017-11-02 WO PCT/JP2017/039680 patent/WO2018084230A1/en active Application Filing
-
2018
- 2018-08-20 HK HK18110632.3A patent/HK1251162B/zh unknown
- 2018-10-02 HK HK18112566.9A patent/HK1253277A1/zh unknown
-
2019
- 2019-05-21 US US16/417,870 patent/US10583129B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
RU2020109376A (ru) | 2020-04-29 |
WO2018084230A1 (en) | 2018-05-11 |
ES2729961T3 (es) | 2019-11-07 |
US20190269663A1 (en) | 2019-09-05 |
BR112018007947A2 (pt) | 2018-10-30 |
RU2018117891A (ru) | 2019-11-18 |
MX2018005715A (es) | 2018-08-09 |
RU2717331C2 (ru) | 2020-03-23 |
RU2018117891A3 (ru) | 2019-11-18 |
CA3000237C (en) | 2019-02-26 |
HK1253277A1 (zh) | 2019-06-14 |
US20180125832A1 (en) | 2018-05-10 |
US10342785B2 (en) | 2019-07-09 |
JP2018535939A (ja) | 2018-12-06 |
EP3344296A1 (en) | 2018-07-11 |
RU2762193C2 (ru) | 2021-12-16 |
HK1251162B (zh) | 2020-01-17 |
JP6516341B2 (ja) | 2019-05-22 |
US10583129B2 (en) | 2020-03-10 |
KR20180064438A (ko) | 2018-06-14 |
CN108289960A (zh) | 2018-07-17 |
EP3344296B1 (en) | 2019-05-15 |
CA3000237A1 (en) | 2018-05-04 |
CN108289960B (zh) | 2021-07-09 |